ASH 2022 | Updated Phase I results from SGNBCMA-001 study of SEA-BCMA in patients with R/R multiple myeloma
Al-Ola Abdallah, MD, University of Kansas Medical Center, Westwood, KS, describes updated results from the Phase I SGNBCMA-001 study (NCT03582033) of SEA-BCMA monotherapy and in combination with dexamethasone or pomalidomide in patients with relapsed/refractory (R/R) multiple myeloma. SEA-BCMA is a monoclonal antibody targeting BCMA to halt myeloma cell proliferation and enhance antibody-dependent cellular phagocytosis and cytotoxicity. The study reported better overall response rates (ORR) in patients treated with an intensive dosing schedule or with dexamethasone relative to standard dosing cohorts. Infusion-related reactions were reported but no hematological, neurological, or ocular toxicities were observed. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
